Shyndec Pharma Gets Registration Certificate for Hypertension Drug

Published on 2025-06-05 at 01:54

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Shyndec Pharmaceutical Unit Gets Registration Certificate for Hypertension Drug in China	07-01	MT
Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	06-05	MT
Shyndec Pharma Gets Registration Certificate for Hypertension Drug	06-05	MT
Shanghai Shyndec Pharmaceutical Gets Approval for Anti-Tumor Injection	05-29	MT
Shyndec Pharmaceutical Unit's Amikacin Sulfate Injection Passes Regulatory Consistency Evaluation	05-14	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-28	CI
Shyndec Pharmaceutical Passes Consistency Evaluation for Antibiotic Drug	04-16	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	03-27	CI
Shyndec Pharmaceutical Subsidiary Passes Generic Drug Consistency Evaluation for Asthma Drug	03-18	MT
Shyndec Pharmaceutical's Unit Gets Registration Certificate for Methylprednisolone Tablets	03-17	MT
Shyndec Pharmaceutical Obtains Registration Certificates for Antiviral, Anticoagulant Drugs	03-10	MT
Shanghai Shyndec Pharmaceutical's Pravastatin Sodium Tablets Passes Chinese Drug Regulator's Consistency Evaluation	03-03	MT
Shyndec Pharma's Units Get Three Drug Registration Certificates	01-22	MT
Shanghai Shyndec's Shenzhen Unit Passes EU GMP Inspection	01-20	MT
Shyndec Pharma Unit's Cefuroxime Sodium for Injection Passes Regulatory Consistency Evaluation	01-20	MT
Shyndec Pharma Gets China Pharmaceutical Ingredient Approval for Anaesthesia Supplementary Drug	01-08	MT
Chinese Drug Regulator Denies Marketing of Shyndec Pharmaceutical's UTI Treatment Drug	01-03	MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(SHSE:600420) added to Shanghai Stock Exchange Health Care Sector Index	12-17	CI
Shanghai Shyndec Pharmaceutical Unit Gets China Nod for Antibiotic Ingredient	12-17	MT
Shyndec Pharmaceutical Unit Gets Nod to Register Cefpodoxime Proxetil Tablets	12-12	MT
Shyndec Pharma Unit's Codeine Phosphate Included in China's Listing of Chemical Raw Materials	12-05	MT
Shanghai Shyndec Pharmaceutical Gets Drug Registration for Eye Drops	12-03	MT
Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection	11-27	MT
Shanghai Shyndec Pharmaceutical CFO Resigns	11-26	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI